Advertisement
Screener

Arbutus Biopharma Corp (ABUS) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Arbutus Biopharma Corp Comprehensive Income

Arbutus Biopharma Corp (ABUS) reported Comprehensive Income of -$5.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12

  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$5.19M, a 307.51% decline year-over-year.
  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $169.60M.
  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$3.73M.
  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$7.68M.
  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$33.46M.
  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$69.63M.
  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$70.78M.
  • Arbutus Biopharma Corp comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$71.61M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-06-30-$5.19M
10-Q · filed 2026-08-12
$164.41M
10-Q · filed 2026-08-12
$160.68M
derived: sum of 3 quarters · filed 2026-08-12
$153.00M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$169.60M
10-Q · filed 2026-05-13
$165.87M
derived: sum of 2 quarters · filed 2026-05-13
$158.19M
derived: sum of 3 quarters · filed 2026-05-13
$160.69M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$3.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$11.41M
derived: sum of 2 quarters · filed 2026-03-23
-$8.91M
derived: sum of 3 quarters · filed 2026-08-12
-$33.46M
10-K · filed 2026-03-23
2025-09-30-$7.68M
10-Q · filed 2025-11-13
-$5.18M
derived: sum of 2 quarters · filed 2026-08-12
-$29.74M
10-Q · filed 2025-11-13
-$42.32M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$2.50M
10-Q · filed 2026-08-12
-$22.05M
10-Q · filed 2026-08-12
-$34.63M
derived: sum of 3 quarters · filed 2026-08-12
-$54.13M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$24.56M
10-Q · filed 2026-05-13
-$37.13M
derived: sum of 2 quarters · filed 2026-05-13
-$56.63M
derived: sum of 3 quarters · filed 2026-05-13
-$76.37M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$12.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$32.08M
derived: sum of 2 quarters · filed 2026-03-23
-$51.81M
derived: sum of 3 quarters · filed 2026-03-23
-$69.63M
10-K · filed 2026-03-23
2024-09-30-$19.50M
10-Q · filed 2025-11-13
-$39.23M
derived: sum of 2 quarters · filed 2025-11-13
-$57.06M
10-Q · filed 2025-11-13
-$75.91M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$19.73M
10-Q · filed 2025-08-06
-$37.56M
10-Q · filed 2025-08-06
-$56.41M
derived: sum of 3 quarters · filed 2025-08-06
-$75.93M
derived: sum of 4 quarters · filed 2025-08-06
2024-03-31-$17.82M
10-Q · filed 2025-05-14
-$36.67M
derived: sum of 2 quarters · filed 2025-05-14
-$56.19M
derived: sum of 3 quarters · filed 2025-05-14
-$73.12M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31-$18.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
-$38.37M
derived: sum of 2 quarters · filed 2025-03-27
-$55.30M
derived: sum of 3 quarters · filed 2025-03-27
-$70.78M
10-K · filed 2025-03-27
2023-09-30-$19.52M
10-Q · filed 2024-11-06
-$36.45M
derived: sum of 2 quarters · filed 2024-11-06
-$51.93M
10-Q · filed 2024-11-06
-$73.35M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30-$16.93M
10-Q · filed 2024-08-08
-$32.41M
10-Q · filed 2024-08-08
-$53.83M
derived: sum of 3 quarters · filed 2024-08-08
-$72.30M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$15.48M
10-Q · filed 2024-05-02
-$36.90M
derived: sum of 2 quarters · filed 2024-05-02
-$55.38M
derived: sum of 3 quarters · filed 2024-05-02
-$70.26M
derived: sum of 4 quarters · filed 2024-05-02
2022-12-31-$21.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05
-$39.89M
derived: sum of 2 quarters · filed 2024-03-05
-$54.77M
derived: sum of 3 quarters · filed 2024-03-05
-$71.61M
10-K · filed 2024-03-05
2022-09-30-$18.47M
10-Q · filed 2023-11-07
-$33.36M
derived: sum of 2 quarters · filed 2023-11-07
-$50.19M
10-Q · filed 2023-11-07
-$71.66M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$14.88M
10-Q · filed 2023-08-03
-$31.72M
10-Q · filed 2023-08-03
-$53.19M
derived: sum of 3 quarters · filed 2023-08-03
-$72.38M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31-$16.84M
10-Q · filed 2023-05-04
-$38.30M
derived: sum of 2 quarters · filed 2023-05-04
-$57.49M
derived: sum of 3 quarters · filed 2023-05-04
-$76.91M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31-$21.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
-$40.66M
derived: sum of 2 quarters · filed 2023-03-02
-$60.08M
derived: sum of 3 quarters · filed 2023-03-02
-$76.41M
10-K · filed 2023-03-02
2021-09-30-$19.19M
10-Q · filed 2022-11-09
-$38.61M
derived: sum of 2 quarters · filed 2022-11-09
-$54.94M
10-Q · filed 2022-11-09
-$72.07M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30-$19.42M
10-Q · filed 2022-08-04
-$35.80M
10-Q · filed 2022-08-04
-$52.88M
derived: sum of 3 quarters · filed 2022-08-04
-$71.67M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$16.38M
10-Q · filed 2022-05-05
-$33.46M
derived: sum of 2 quarters · filed 2022-05-05
-$52.25M
derived: sum of 3 quarters · filed 2022-05-05
-$66.21M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31-$17.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03
-$35.87M
derived: sum of 2 quarters · filed 2022-03-03
-$49.83M
derived: sum of 3 quarters · filed 2022-03-03
-$63.69M
10-K · filed 2022-03-03
2020-09-30-$18.78M
10-Q · filed 2021-11-04
-$32.75M
derived: sum of 2 quarters · filed 2021-11-04
-$46.60M
10-Q · filed 2021-11-04
-$71.02M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$13.96M
10-Q · filed 2021-08-05
-$27.82M
10-Q · filed 2021-08-05
-$52.24M
derived: sum of 3 quarters · filed 2021-08-05
-$134.72M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31-$13.61M
10-Q · filed 2021-05-05
-$38.28M
derived: sum of 2 quarters · filed 2021-05-05
-$120.75M
derived: sum of 3 quarters · filed 2021-05-05
-$144.12M
derived: sum of 4 quarters · filed 2021-05-05
2019-12-31-$24.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
-$107.14M
derived: sum of 2 quarters · filed 2021-03-04
-$130.51M
derived: sum of 3 quarters · filed 2021-03-04
-$153.78M
10-K · filed 2021-03-04
2019-09-30-$82.48M
10-Q · filed 2020-11-05
-$105.84M
derived: sum of 2 quarters · filed 2020-11-05
-$129.12M
10-Q · filed 2020-11-05
-$147.34M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$23.37M
10-Q · filed 2020-08-07
-$46.64M
10-Q · filed 2020-08-07
-$64.86M
derived: sum of 3 quarters · filed 2020-08-07
-$89.35M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31-$23.27M
10-Q · filed 2020-05-11
-$41.49M
derived: sum of 2 quarters · filed 2020-05-11
-$65.98M
derived: sum of 3 quarters · filed 2020-05-11
-$62.89M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31-$18.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05
-$42.71M
derived: sum of 2 quarters · filed 2020-03-05
-$39.62M
derived: sum of 3 quarters · filed 2020-03-05
-$57.05M
10-K · filed 2020-03-05
2018-09-30-$24.48M
10-Q · filed 2019-11-06
-$21.39M
derived: sum of 2 quarters · filed 2019-11-06
-$38.82M
10-Q · filed 2019-11-06
-$74.75M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30$3.09M
10-Q · filed 2019-08-05
-$14.34M
10-Q · filed 2019-08-05
-$50.27M
derived: sum of 3 quarters · filed 2019-08-05
-$61.87M
derived: sum of 4 quarters · filed 2019-08-05
2018-03-31-$17.43M
10-Q · filed 2019-05-06
-$53.36M
derived: sum of 2 quarters · filed 2019-05-06
-$64.96M
derived: sum of 3 quarters · filed 2019-05-06
2017-12-31-$35.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
-$47.53M
derived: sum of 2 quarters · filed 2019-03-07
-$84.41M
10-K · filed 2019-03-07
2017-09-30-$11.60M
10-Q · filed 2018-11-07
-$48.48M
10-Q · filed 2018-11-07
2016-12-31-$218.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
-$238.29M
derived: sum of 2 quarters · filed 2018-03-16
-$368.29M
derived: sum of 3 quarters · filed 2018-03-16
-$384.16M
10-K · filed 2018-03-16
2016-09-30-$19.59M
10-Q · filed 2016-11-03
-$149.59M
derived: sum of 2 quarters · filed 2016-11-03
-$165.47M
10-Q · filed 2016-11-03
-$178.93M
derived: sum of 4 quarters · filed 2018-03-16
2016-06-30-$130.00M
10-Q · filed 2016-08-04
-$145.87M
10-Q · filed 2016-08-04
-$159.33M
derived: sum of 3 quarters · filed 2018-03-16
-$198.41M
derived: sum of 4 quarters · filed 2018-03-16
2016-03-31-$15.87M
10-Q · filed 2016-05-04
-$29.33M
derived: sum of 2 quarters · filed 2018-03-16
-$68.42M
derived: sum of 3 quarters · filed 2018-03-16
-$80.08M
derived: sum of 4 quarters · filed 2018-03-16
2015-12-31-$13.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
-$52.54M
derived: sum of 2 quarters · filed 2018-03-16
-$64.20M
derived: sum of 3 quarters · filed 2018-03-16
-$88.59M
10-K · filed 2018-03-16
2015-09-30-$39.08M
10-Q · filed 2016-11-03
-$50.75M
derived: sum of 2 quarters · filed 2016-11-03
-$75.13M
10-Q · filed 2016-11-03
-$81.36M
derived: sum of 4 quarters · filed 2017-03-22
2015-06-30-$11.66M
10-Q · filed 2016-08-04
-$32.83M
10-Q · filed 2016-08-04
-$42.27M
derived: sum of 3 quarters · filed 2017-03-22
-$55.70M
derived: sum of 4 quarters · filed 2017-03-22
2015-03-31-$21.16M
10-Q · filed 2016-05-04
-$30.61M
derived: sum of 2 quarters · filed 2017-03-22
-$44.04M
derived: sum of 3 quarters · filed 2017-03-22
-$46.35M
derived: sum of 4 quarters · filed 2017-03-22
2014-12-31-$9.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22
-$22.88M
derived: sum of 2 quarters · filed 2017-03-22
-$25.18M
derived: sum of 3 quarters · filed 2017-03-22
-$45.33M
10-K · filed 2017-03-22
2014-09-30-$13.43M
10-Q · filed 2015-11-05
-$15.74M
derived: sum of 2 quarters · filed 2015-11-05
-$35.88M
10-Q · filed 2015-11-05
-$40.21M
derived: sum of 4 quarters · filed 2016-03-09
2014-06-30-$2.31M
10-Q · filed 2015-08-07
-$22.45M
10-Q · filed 2015-08-07
-$26.78M
derived: sum of 3 quarters · filed 2016-03-09
-$31.98M
derived: sum of 4 quarters · filed 2016-03-09
2014-03-31-$20.14M
10-Q · filed 2015-05-06
-$24.48M
derived: sum of 2 quarters · filed 2016-03-09
-$29.67M
derived: sum of 3 quarters · filed 2016-03-09
-$33.92M
derived: sum of 4 quarters · filed 2016-03-09
2013-12-31-$4.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09
-$9.53M
derived: sum of 2 quarters · filed 2016-03-09
-$13.78M
derived: sum of 3 quarters · filed 2016-03-09
-$17.20M
10-K · filed 2016-03-09
-$17.20M
6-K · filed 2014-03-06
2013-09-30-$5.20M
10-Q · filed 2014-11-07
-$9.45M
derived: sum of 2 quarters · filed 2014-11-07
-$12.87M
10-Q · filed 2014-11-07
2013-06-30-$4.25M
10-Q · filed 2014-08-14
-$7.67M
10-Q · filed 2014-08-14
2013-03-31-$3.42M
10-Q · filed 2014-05-14
2012-12-31$30.09M
10-K · filed 2015-03-13
$30.09M
6-K · filed 2014-03-06
2011-12-31-$10.14M
10-K · filed 2014-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Apnimed, Inc. (APMD)United States$0.899B
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Savara Inc (SVRA)United States$1.044B-9.10
Theravance Biopharma, Inc. (TBPH)$0.885B16.40